billwanhua
本站元老
- 注册
- 2005-07-07
- 消息
- 15,790
- 荣誉分数
- 5,019
- 声望点数
- 373
Biogen faces tough questions over $56K-a-year price of newly approved Alzheimer's drug
Biogen on Tuesday faced tough questions from Wall Street analysts over the $56,000 annual cost of its newly approved Alzheimer's drug, Aduhelm.
www.cnbc.com
批评的声音:
1.太贵,每年5.6万美元
2.独立专家评估不一定有效。The FDA departed from the advice of its independent panel of outside experts, who unexpectedly declined to endorse the drug last fall, citing unconvincing data. 专家组8-1否定,FDA依然通过。
Biogen hits snag after Alzheimer's drug fails to win support from FDA panel
If fully approved, it would be the first drug to slow cognitive decline in people living with the disease and the first new treatment for Alzheimer's in nearly 20 years.
www.cnbc.com